Since METTL3 inactivates CD8+ T cells in NAFLD-HCC microenvironment, this prompted us to explore whether targeting METTL3 could improve ICB therapeutic efficacy for NAFLD-HCC. The gene discussed is METTL3; the disease is hepatocellular carcinoma.